Alastair Smith of Avacta: Successful Completion of Fourth Dose Escalation in AVA6000 Study
Episode 1128, Jan 17, 2023, 01:32 PM
Share
Subscribe
In this fascinating conversation - Alastair Smith, CEO of Avacta #AVCT takes Vox Markets through today’s excellent news with regards to the Phase 1a clinical trial data for AVA6000.